Qualcomm Backs Ultrahuman’s $70M Push to Turn Smart Rings Into Computers
Qualcomm backs Ultrahuman’s $70M round as the $365M smart-ring maker targets on-device AI, developer apps and a $200M revenue run rate by January 2027.
Summary
On September 3, 2026, Bengaluru-based Ultrahuman raised $70 million, comprising $65 million in primary equity and $5 million in debt, at a $365 million valuation, roughly triple its $120 million valuation in 2023. Qualcomm Ventures joined Labcorp, Alpha Wave, Blume Ventures, Nexus Venture Partners and Alteria Capital. Founder and CEO Mohit Kumar said Ultrahuman and Qualcomm are developing a later ring using Qualcomm silicon while retaining Nordic Semiconductor chips. Greater on-device computing should reduce phone and cloud dependence. By late September, Ring Air and Ring Pro updates will add AI interaction, game controls and third-party development. Future uses include a pointer, mouse, car key and physiology-aware controller. Qualcomm Ventures head Quinn Li describes the concept as an always-on personal AI device.
Annual revenue run rate is $140 million, up about 45% year over year, with $200 million targeted by January 2027. Ultrahuman has sold 800,000 rings, versus 700,000 in February 2026, while 12% of users buy PowerPlugs subscriptions. Kumar and Vatsal Singhal founded Ultrahuman in 2019 around continuous glucose monitors before expanding into rings, blood testing and environmental sensing. The US, now 45% of quarterly revenue versus India’s 11%, remains its largest market. An Oura patent dispute halted Ring Air sales there for much of the past year, but the redesigned Ring Pro returned in 2026 and demand is 18 to 20 times supply. Ultrahuman expects previous US volumes next quarter and aims to triple them over the following four quarters.
Capital will fund India and UAE retail expansion, including offline touchpoints such as Bengaluru’s Performance Center, plus clinical research and product development. Higher spending could prevent profitability in 2026. Ultrahuman wants eight profitable quarters before listing, requiring an estimated eight to 10 quarters, with 2028 the earliest IPO window, while Oura is eyeing a September IPO. Labcorp and Ultrahuman are exploring whether ring blood-flow signals combined with blood tests can identify cardiovascular, fertility and aging risks. Labcorp executive Megann Vaughn Watters sees personalized-health potential, but integration details remain undisclosed and further announcements are expected soon.
Positives
- The $70 million round values Ultrahuman at $365 million, roughly three times its $120 million valuation in 2023.
- Ring Air and Ring Pro will gain AI interaction, game controls and third-party development through a late-September software update.
- Annual revenue run rate reached $140 million, up about 45%, with $200 million targeted by January 2027.
- Ultrahuman has sold about 800,000 rings, while Ring Pro demand is running at 18 to 20 times available US supply.
- Labcorp is exploring cardiovascular, fertility and aging applications combining ring blood-flow signals with blood-test data.
Risks & concerns
- An Oura patent dispute stopped US Ring Air sales for much of the past year, disrupting Ultrahuman’s largest market.
- Ring Pro demand is 18 to 20 times available US supply, exposing a substantial production bottleneck.
- Higher spending on stores, branding, clinical studies and product development could leave Ultrahuman unprofitable in 2026.
- A public listing is unlikely before 2028 because Ultrahuman wants eight consecutive profitable quarters first.
- Labcorp integration details remain undisclosed, leaving the timing and commercial form of diagnostic features uncertain.